GlobeNewsWire
24 Oct 2026, 06:30 UTC · 2h ago
Impact · against what's priced in
Immatics provides updated clinical data for its PRAME-targeting bispecific and cell therapy programs. While positive, the announcement represents expected clinical progression for a Phase 1/1b stage biotech.
No priced-in read yet
Which stocks this story touches
More positive than 71% of ticker scores this week
The company is announcing updated clinical trial data for its cell therapy and bispecific programs.
Continue reading
5 related stories
The company is reporting updated clinical activity for IMA402 and IMA203CD8 in advanced solid tumors, providing fresh data points on its precision targeting platform.
Read from the article alone
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Invezz
14h ago
—
IMTX hasn't traded since this ran. Last close $7.31 (Oct 23); the reaction starts at the next open.
IMTX chart →
